

Revision date: 04-Jan-2011 Version: 1.0 Page 1 of 7

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Animal Health Pfizer Ltd. Pfizer Inc Kent 235 East 42nd Street **CT13 9NJ** New York, NY 10017 **United Kingdom** +00 44 (0)1304 616161

Poison Control Center Phone: 1-866-531-8896 Technical Services Phone: 1-800-366-5288

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com **Emergency telephone number:**

ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: FluSure XP®/RespiSure (H1N2)

FluSure™ XP/RespiSure® (H1N2) Trade Name:

Synonyms: Swine Influenza Vaccine, H1N1, H1N2, H3N2, Killed Virus-Mycoplasma Hyopneumoniae

Bacterin

Mixture **Chemical Family:**

Intended Use: Veterinary Vaccine

2. HAZARDS IDENTIFICATION

Appearance: Veterinary vaccine pellets plus a liquid adjuvanted preparation

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: In the event of accidental injection, an allergic reaction may occur. If an allergic reaction

occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted. This product is an oil-adjuvanted suspension. Oil-adjuvant containing

products may cause severe vasospasm following accidental injection.

EU Indication of danger: Not classified

Australian Hazard Classification

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

This document has been prepared in accordance with standards for workplace safety, which Note:

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Mineral oil	8012-95-1	232-384-2	Not Listed	*
Gentamicin	1403-66-3	215-765-8	Not Listed	*

Material Name: FluSure XP®/RespiSure (H1N2)

Revision date: 04-Jan-2011

Page 2 of 7

Version: 1.0

3. COMPOSITION/INFORMATION ON INGREDIENTS							
Merthiolate (as mercury)	54-64-8	200-210-4	N; R50/53 R33 T+; R26/27/28	##			

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Swine Influenza Virus A, strain H1N1	NOT ASSIGNED	Not Listed	Not Listed	*
Swine Influenza Virus A, strain H3N2	NOT ASSIGNED	Not Listed	Not Listed	*
Sorbitan monooleate	1338-43-8	215-665-4	Not Listed	*
Mycoplasma Hyopneumoniae	NOT ASSIGNED	Not Listed	Not Listed	*
Polyoxyethylene (20) sorbitan monooleate	9005-65-6	Not Listed	Not Listed	*
Swine Influenza Virus A, strain H1N2	Not Assigned	Not Listed	Not Listed	*
Amphigen	MIXTURE	Not Listed	Not Listed	*

Additional Information: * Proprietary

Trace Ingredient(s) indicated as hazardous have been assessed under standards for

workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Notes to Physician: Where parenteral oil-adjuvanted vaccine exposure has occurred, the patient should be

promptly evaluated for the development of vasospasm and/or compartment syndrome.

5. FIRE FIGHTING MEASURES

Extinguishing Media: As for primary cause of fire.

Hazardous Combustion Products: Not known

Fire Fighting Procedures: Dike and collect water used to fight fire.

Fire / Explosion Hazards: Not applicable

Additional Information: This product is a nonflammable aqueous solution. This material is not expected to

support combustion.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Material Name: FluSure XP®/RespiSure (H1N2)

Revision date: 04-Jan-2011

Page 3 of 7

Version: 1.0

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Use with adequate ventilation. Avoid contact with eyes, skin and clothing. Avoid breathing

dust, vapor or mist.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Mineral oil

ACGIH Threshold Limit Value (TWA) 5 mg/m³ TWA
ACGIH Threshold Limit Value (STEL) 10 mg/m³ STEL

Listed **ACGIH OELs - Notice of Intended Changes Australia TWA** 5 mg/m³ **Belgium OEL - TWA** Listed Listed **Bulgaria OEL - TWA** Czech Republic OEL - TWA Listed **Denmark OEL - TWA** Listed **Finland OEL - TWA** Listed **Greece OEL - TWA** Listed Ireland OEL - TWAs Listed **Netherlands OEL - TWA** Listed **OSHA - Final PELS - TWAs:** 5 mg/m³ Poland OEL - TWA Listed Listed Portugal OEL - TWA Listed Romania OEL - TWA Spain OEL - TWA Listed Sweden OEL - TWAs Listed

Gentamicin

Bulgaria OEL - TWA Listed

Merthiolate (as mercury)

ACGIH Threshold Limit Value (TWA) 0.01 mg/m³ TWA
ACGIH Threshold Limit Value (STEL) 0.03 mg/m³ STEL

ACGIH - Skin Absorption Designation Listed 0.03 mg/m³ **Australia STEL Australia TWA** 0.01 mg/m^3 Austria OEL - MAKs Listed Listed **Belgium OEL - TWA Bulgaria OEL - TWA** Listed **Bulgaria - Biological Exposure Limit:** Listed Czech Republic OEL - TWA Listed

Material Name: FluSure XP®/RespiSure (H1N2)

Revision date: 04-Jan-2011

Page 4 of 7

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Denmark OEL - TWA Estonia OEL - TWA Listed **Finland OEL - TWA** Listed France OEL - TWA Listed **Germany - Biological Exposure Limit:** Listed Listed **Greece OEL - TWA Hungary OEL - TWA** Listed **Ireland OEL - TWAs** Listed Lithuania OEL - TWA Listed **OSHA - Final PELS - TWAs:** 0.01 mg/m^3 **Poland OEL - TWA** Listed Portugal OEL - TWA Listed **Romania - Biological Exposure Limit:** Listed Slovak Republic - Biological Exposure Limit: Listed Slovenia OEL - TWA Listed Spain OEL - TWA Listed Sweden OEL - TWAs Listed

Engineering Controls: General room ventilation is adequate unless the process generates dust, mist or fumes.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Wear impervious gloves if skin contact is possible.

Eyes: Safety glasses or goggles

Skin: Wear protective clothing when working with large quantities.

Respiratory protection: Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection,

with appropriate protection factors, should be used to minimize exposure.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Pellets plus sterile diluent Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solubility: Soluble: Water (based on components)

pH: 7.0 +/- 1.5 **Boiling Point (°C):** >100

Vapor Pressure (kPa): Expected to be negligible

Specific Gravity: 1.0 +/-0.2

Flash Point (Liquid) (°C):

Polymerization:

Non-flammable
Will not occur

10. STABILITY AND REACTIVITY

Chemical Stability: Stable

Conditions to Avoid: Store at 2-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do

not freeze.

Incompatible Materials: This material can be denatured or inactivated by a variety of organic solvents, salts or heavy

metals.

Material Name: FluSure XP®/RespiSure (H1N2)

Revision date: 04-Jan-2011

Page 5 of 7

Version: 1.0

10. STABILITY AND REACTIVITY

Hazardous Decomposition Products: None expected under normal conditions.

11. TOXICOLOGICAL INFORMATION

General Information: The antigens included in this product are non-infectious. All have been prepared from killed or

inactivated preparations of microorganisms. The information included in this section describes

the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Gentamicin

Rat Oral LD50 6600 mg/kg

Rat Subcutaneous LD50 710 mg/kg

Mouse IM LD50 167 mg/kg Rat IM LD50 463 mg/kg

Merthiolate (as mercury)

Rat Oral LD50 75 mg/kg

Rat Subcutaneous LD50 98 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Gentamicin

Eye Irritation Rabbit Non-irritating

Merthiolate (as mercury)

Eye Irritation Rabbit Mild

Mineral oil

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Gentamicin

Embryo / Fetal Development Rat Intramuscular 75 mg/kg/day LOAEL Developmental toxicity

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Mineral oil

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Releases to the environment should be avoided. The environmental characteristics of this

material have not been fully evaluated.

Material Name: FluSure XP®/RespiSure (H1N2)

Revision date: 04-Jan-2011

Page 6 of 7

Version: 1.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. This product contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP).

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Sorbitan monooleate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

obligations of Register:

EU EINECS/ELINCS List 215-665-4

Mineral oil

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

232-384-2

Gentamicin

California Proposition 65 Aminoglycosides- developmental

Material Name: FluSure XP®/RespiSure (H1N2)

Revision date: 04-Jan-2011

Page 7 of 7

Version: 1.0

15. REGULATORY INFORMATION

Australia (AICS): Listed
Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 215-765-8

Polyoxyethylene (20) sorbitan monooleate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Listed

Merthiolate (as mercury)

CERCLA/SARA 313 Emission reporting 1.0% Supplier notification limit

California Proposition 65 Developmental

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Listed

REACH - Annex XVII - Restrictions on Certain

Dangerous Substances:

EU EINECS/ELINCS List 200-210-4

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R33 - Danger of cumulative effects.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety

data sheets for individual ingredients.

Prepared by: Product Stewardship Hazard Communications

Pfizer Global Environment, Health, and Safety Operations

Use restricted. See item 18.

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
